{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:40:36Z","timestamp":1791319236002,"version":"4.3.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.ejpb.2013.06.006","type":"journal-article","created":{"date-parts":[[2013,6,22]],"date-time":"2013-06-22T12:46:50Z","timestamp":1371905210000},"page":"1300-1309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"PB","title":["Orally disintegrating tablet of novel salt of antiepileptic drug: Formulation strategy and evaluation"],"prefix":"10.1016","volume":"85","author":[{"given":"Ziyaur","family":"Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhtar","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2013.06.006_b0005","series-title":"Adherence to Long-term Therapies: Evidence for Action","author":"Sabat\u00e9","year":"2003"},{"key":"10.1016\/j.ejpb.2013.06.006_b0010","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1001\/jama.296.21.joc60162","article-title":"Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial","volume":"296","author":"Lee","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ejpb.2013.06.006_b0015","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2013.06.006_b0020","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4065\/mcp.2010.0575","article-title":"Medication adherence: WHO cares?","volume":"86","author":"Brown","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ejpb.2013.06.006_b0025","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2147\/TCRM.S1458","article-title":"Factors affecting therapeutic compliance: a review from the patient\u2019s perspective","volume":"4","author":"Jin","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.ejpb.2013.06.006_b0030","unstructured":"American Academy of Pediatrics, Periodic Survey #44 Patient Compliance with Prescription Regimens, 2000 <http:\/\/www.aap.org\/en-us\/professional-resources\/Research\/pages\/PS44_Executive_Summary_PatientCompliancewithPrescriptionRegimens.aspx?nfstatus=401&nftoken=00000000-0000-0000-0000-000000000000&nfstatusdescription=ERROR%3a+No+local+token> (accessed on 17.01.13)."},{"key":"10.1016\/j.ejpb.2013.06.006_b0035","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1208\/s12249-009-9237-y","article-title":"Formulation design and optimization of novel taste masked mouth dissolving tablets of tramadol having adequate mechanical strength","volume":"10","author":"Madgalkar","year":"2009","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2013.06.006_b0040","doi-asserted-by":"crossref","first-page":"633","DOI":"10.4155\/tde.12.28","article-title":"Improvement of the bitter taste of drugs by complexation with cyclodextrins: applications, evaluations and mechanisms","volume":"3","author":"Arima","year":"2012","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.ejpb.2013.06.006_b0045","unstructured":"N. Nouri, J.M. Zuccarelli, C. Chauveau, E. Bruna, Process for Manufacturing Coated Granules with Masked Taste and Immediate Release of the Active Principle, U.S. Patent 6,660,382, 2003."},{"key":"10.1016\/j.ejpb.2013.06.006_b0050","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1023\/A:1015958417047","article-title":"Improved buccal delivery of opioid analgesics and antagonists with bitterless prodrugs","volume":"5","author":"Hussain","year":"1988","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2013.06.006_b0055","article-title":"Taste-masking compositions","volume":"EP0212641","author":"Damini","year":"1987","journal-title":"EP Appl."},{"key":"10.1016\/j.ejpb.2013.06.006_b0060","unstructured":"M. Nishikawa, H. Hayashi, Composition for Antitussive Expectorant Reduced in its Bitter Taste, 1993."},{"key":"10.1016\/j.ejpb.2013.06.006_b0065","article-title":"Patient adherence to transdermal rivastigmine after switching from oral donepezil: a retrospective claims database study","author":"Tian","year":"2012","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.ejpb.2013.06.006_b0070","first-page":"178","article-title":"Mirtazapine therapy for dysgeusia in an elderly patient prim care companion","volume":"8","author":"Padala","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejpb.2013.06.006_b0075","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/PPA.S27344","article-title":"Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties","volume":"6","author":"Montgomery","year":"2012","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.ejpb.2013.06.006_b0080","unstructured":"Food and Drug Administration Draft Guidance for Industry, Orally Disintegrating Tablets, Rockville, Maryalnd, USA, 2003."},{"key":"10.1016\/j.ejpb.2013.06.006_b0085","unstructured":"J. Susan, FDA Warns of Aseptic Meningitis Risk with Lamotrigine, Medscape Medical News, 2010."},{"key":"10.1016\/j.ejpb.2013.06.006_b0090","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1021\/cg301556j","article-title":"Crystal structures and physicochemical properties of four new lamotrigine multicomponent forms","volume":"13","author":"Chadha","year":"2013","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejpb.2013.06.006_b0095","doi-asserted-by":"crossref","first-page":"183","DOI":"10.5138\/ijdd.2010.0975.0215.02028","article-title":"Design and evaluation of taste masked chewable dispersible tablet of lamotrigine by melt granulation","volume":"2","author":"Amrutkar","year":"2010","journal-title":"Int. J. Drug Deliv."},{"key":"10.1016\/j.ejpb.2013.06.006_b0100","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1208\/s12249-012-9800-9","article-title":"Improvement of physicochemical properties of an antiepileptic drug by salt engineering","volume":"13","author":"Rahman","year":"2012","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2013.06.006_b0105","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/00401706.1960.10489912","article-title":"Some new three level designs for the study of quantitative variables","volume":"2","author":"Box","year":"1960","journal-title":"Technometrics"},{"key":"10.1016\/j.ejpb.2013.06.006_b0110","unstructured":"United States Pharmacopiea-35-National Formulary-30, Uniformity of dosage units (905), Rockville, Maryland, United States 420, 2013."},{"key":"10.1016\/j.ejpb.2013.06.006_b0115","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ijpharm.2012.07.037","article-title":"Cholorpheniramine tannate complexes: physicochemical, chemometric, and taste masking evaluation","volume":"436","author":"Rahman","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2013.06.006_b0120","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/jps.21928","article-title":"Spectral and spatial characterization of protein loaded PLGA nanoparticles","volume":"99","author":"Zidan","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2013.06.006_b0125","first-page":"125","article-title":"Effect of compression force, humidity and disintegrant concentration on the disintegration and dissolution on directly compressed furosemide tablets using crosscarmellose sodium as disintegrant","volume":"2","author":"Marais","year":"2003","journal-title":"Trop. J. Pharm. Res."},{"key":"10.1016\/j.ejpb.2013.06.006_b0130","doi-asserted-by":"crossref","first-page":"279","DOI":"10.17305\/bjbms.2007.3060","article-title":"Effect of magnesium stearate concentration on dissolution properties of ranitidine hydrochloride coated tablets","volume":"7","author":"Uzunovi\u0107","year":"2007","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"10.1016\/j.ejpb.2013.06.006_b0135","first-page":"500","article-title":"Evaluation of the disintegration properties of microcrystalline cellulose II and commercial disintegrants","volume":"67","author":"Rojas","year":"2012","journal-title":"Pharmazie"},{"key":"10.1016\/j.ejpb.2013.06.006_b0140","unstructured":"S. Ali, C. Santos, Crospovidone in development of directly compressible tablets, in: AAPS Annual Meeting and Exposition, Los Angeles, CA, USA, November 2009."},{"key":"10.1016\/j.ejpb.2013.06.006_b0145","unstructured":"S. Ali, N. Langley, Formulation \u2013 excipients: dry granulation simplifies tableting process, Pharm. Formul. Qual., April\/May 2010 <http:\/\/www.pharmaquality.com\/ME2\/Audiences\/dirmod.asp?nm=Browse+Articles&type=Publishing&mod=Publications%3A%3AArticle&mid=D3E3C719D8D44216836DCA4F4144BEC4&tier=4&id=48FF555BC38E4A16BD5989CF0608B1C1&AudID=5648A5C28C97462DBBDB309539B820EF> (accessed on 19.02.13)."},{"key":"10.1016\/j.ejpb.2013.06.006_b0150","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0032-5910(88)80047-0","article-title":"Magnesium stearate susceptibility of directly compressible materials as an indication of fragmentation properties","volume":"54","author":"Vromans","year":"1988","journal-title":"Powder Technol."},{"key":"10.1016\/j.ejpb.2013.06.006_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2010.01.007","article-title":"Lubrication in tablet formulations","volume":"75","author":"Wang","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2013.06.006_b0160","unstructured":"United States Pharmacopiea-35-National Formulary-30. Lamotrigine tablet monogram. Rockville, Maryland, United States 3637, 2013."},{"key":"10.1016\/j.ejpb.2013.06.006_b0165","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/jps.2600531122","article-title":"Relationship between rate of dissolution, disintegration time, and physiological availability of riboflavin in sugar-coated tablets","volume":"53","author":"Middleton","year":"1964","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2013.06.006_b0170","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1016\/j.foodchem.2012.06.021","article-title":"Discrimination of mineral waters by electronic tongue, sensory evaluation and chemical analysis","volume":"135","author":"Sipos","year":"2012","journal-title":"Food Chem."},{"key":"10.1016\/j.ejpb.2013.06.006_b0175","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijpharm.2008.09.042","article-title":"Evaluation of a taste sensor instrument (electronic tongue) for use in formulation development","volume":"367","author":"Lorenz","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2013.06.006_b0180","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijpharm.2011.10.033","article-title":"Tannate complexes of antihistaminic drug: sustained release and taste masking approaches","volume":"422","author":"Rahman","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2013.06.006_b0185","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jpba.2011.02.002","article-title":"A comparative study on two electronic tongues for pharmaceutical formulation development","volume":"55","author":"Woertz","year":"2011","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejpb.2013.06.006_b0190","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1081\/DDC-120037477","article-title":"Taste masking technologies in oral pharmaceuticals: recent developments and approaches","volume":"30","author":"Sohi","year":"2004","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2013.06.006_b0195","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1117\/12.472076","article-title":"Hyperspectral imaging technology for pharmaceutical analysis","volume":"4626","author":"Hamilton","year":"2002","journal-title":"Proc. SPIE"},{"key":"10.1016\/j.ejpb.2013.06.006_b0200","first-page":"40","article-title":"NIR chemical imaging for counterfeit pharmaceutical products analysis","volume":"22","author":"Dubois","year":"2007","journal-title":"Spectroscopy"},{"key":"10.1016\/j.ejpb.2013.06.006_b0205","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1002\/jps.21230","article-title":"Characterization of pharmaceutical powder blends by NIR chemical imaging","volume":"97","author":"Ma","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2013.06.006_b0210","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejpb.2007.10.013","article-title":"Recent applications of chemical imaging to pharmaceutical process monitoring and quality control","volume":"69","author":"Gowen","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2013.06.006_b0215","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.aca.2011.03.048","article-title":"Comparison of near infrared and microwave resonance sensors for at-line moisture determination in powders and tablets","volume":"696","author":"Corredor","year":"2011","journal-title":"Anal. Chim. Acta"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641113002245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641113002245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T02:28:16Z","timestamp":1563244096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641113002245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0939641113002245"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2013.06.006","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Orally disintegrating tablet of novel salt of antiepileptic drug: Formulation strategy and evaluation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2013.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}